BofA keeps Neutral on Pfizer after danuglipron failure as core thesis unchanged
Bofa Anderson analyst Pfizer (Pfizer) notes (PFEDanuglipron, an oral GLP-1 obesity, is stopped, after a case of liver injury seen in the study of the first stage. The company indicates that it has argued that this program may have…